匹多莫德对哮喘患儿白介素16及免疫机制的影响  

The influence of pidotimod on the interleukin 16 and immune mechanisms in children with asthma

作　　者：徐小龙[1] 

机构地区：[1]浙江省慈溪市人民医院儿科,浙江慈溪315300

出　　处：《中国现代医生》2012年第9期1-3,共3页China Modern Doctor

摘　　要：目的探讨匹多莫德对哮喘患儿的临床疗效,进一步探讨其及对白介素16(IL-16)、免疫球蛋白、T细胞亚群等各项免疫学指标的影响,旨在阐明其对哮喘患儿的免疫作用机制。方法将70例诊断为哮喘的患儿按随机数字表分为观察组(常规治疗+匹多莫德)和对照组(常规治疗)各35例,两组疗程均为60 d,疗程结束后,比较两组的临床疗效、哮喘发作次数,肺功能治疗前后的变化情况,以及两组治疗后2个月患儿IL-16、IL-4、INF-γ及血清IgA、IgG、IgM水平,T淋巴细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)水平。结果 (1)观察组治疗后的总有效率达91.4%,明显高于对照组(P<0.05)。(2)观察组哮喘患儿治疗后不同时间的哮喘发作次数均明显少于对照组(P<0.05)。(3)观察组哮喘患儿的FEV1(L)、FEV1/FVC(%)、FEV1占预计值(%)治疗后均较治疗前及对照组显著提高(P<0.05)。(4)观察组治疗后的IgG、IgA、IgM等均较治疗前明显升高,且高于对照组(P<0.05)。观察组治疗后CD3+、CD4+、CD4+/CD8+均较治疗前明显升高,且明显高于对照组,而CD8+较治疗前明显降低,且观察组明显低于对照组(P<0.05)。观察组治疗后IL-16、IL-4均较治疗前明显降低,且观察组较对照组降低更明显,观察组治疗后INF-γ较治疗前明显升高,且明显高于对照组(P<0.05)。结论匹多莫德对哮喘患儿临床疗效确切,能有效控制哮喘的发作次数,降低IL-16水平,改善哮喘患儿的肺功能,不良反应少,考虑可能通过调节其免疫机制而发挥作用的。Objective To investigate the clinical efficacy of pidotimod threatment children with asthma,and further to explore the expression of IL-16, immunoglobulin, T cell subsets and other immunological indexes changes. Methods All of 70 cases children with asthma were randomly divided into two groups, each group 35 patients, after treatment, to compare the clinical efficacy and the asthma attacks number, lung function changes,and the changes of IL-16, IL-4, INF-γ and serum lgA, lgG, IgM levels, T lymphocyte subsets （CD3＋, CD4＋, CD8＋, CD4＋/CD8＋） levels. Results （1） After treatment,the total effective rate of the observation was 91.4%, and it was significantly higher than the control group （P 〈 0.05）. （2）after treatment, the asthma attacks of the observation group at different times were significantly less than the control group （P 〈 0.05）. （3） after treatment,the observation group of FEV 1 （L） ,FEV 1/FVC（%）,FEV 1 percentage of predicted value （%） was significantly increased than before treatment and the control group （P 〈 0.05）. （4） After treatment,the IgG, IgA, IgM, etc w4＋ significantly higher than those before treatment and the control group （P 〈 0.05）. After treatment, CD3＋, CD4＋, CD4＋/CD8＋ was significantly higher than before treatment, after treatment, CD8＋ of the observation group was significantly lower than before treatment and the control group （P 〈 0.05）. After treatment,IL-16, IL-4 of the two groups was significantly lower than before treatment, and the observation group decreased more significantly than control group after treatment, INF-γ was significantly higher than that before treatment （P 〈 0.05）. Conclusion Pidotimod has clinical efficacy for the children with asthma, and can effective control asthma attacks, reduce 1L-16 levels, improve lung function, and have no adverse reactions, it is worthy of applying.

关 键 词：匹多莫德 哮喘 白介素16 免疫球蛋白 T细胞亚群 

分 类 号：R725[医药卫生—儿科]